Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct — Euphrasia  

Preterm Neonates Clinical Trial

Official title: Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct - a Randomized Double-blind Controlled Trial

Status Completed

Clinical Trial Summary

Congenital nasolacrimal duct obstruction (CNLDO) occurs in approximately 10 to 20% of all term newborns, and is the most common cause of persistent tearing and ocular discharge in children. CNLDO causes symptoms in up to 6% of children during the first year of life. The first clinical signs appear during the first month of life in 95% of cases and usually consist of tearing and debris on the eyelashes ("mattering"). Mucopurulent eye discharge occurs commonly in infants with CNLDO and, in the absence of other signs of infection, suggests bacterial overgrowth in the stagnant tear pool of the lacrimal sac.

This study investigates whether early administration of Euphrasia eye drops (Weleda AG, Arlesheim) in preterm neonates presenting with first ocular discharge with or without tearing and reddened eye fosters the resolution of the ocular discharge and reduces the need for topical antibiotic therapy.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Congenita Nasolacrimal Duct Obstruction
• Ocular Discharge
• Premature Birth
• Preterm Neonates

• NCT number: NCT04122300
• Study type: Interventional
• Source: University of Bern
• Status: Completed
• Phase: Phase 3
• Start date: May 22, 2011
• Completion date: December 16, 2016